Astrazeneca Ab

Astra Aktiebolag

Tomas Eriksson

Magnus Leif Lindvall

Tomas Klingstedt

Kostas Karabelas

Krister Henriksson

H&aring;kan Bergstrand

Bengt S&auml;rnstrand

Tesfaledet Mussie

Martin Hemmerling

Peter Hansen

Hans Lönn

Svetlana Ivanova

Bengt Olof Sarnstrand

Karolina Lawitz

Lars Pettersson

Hangkan Sten Bergstrand

Johan Hansson

Michael Bodkin

The invention provides compounds of general formula (D wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. 

Compounds

The invention provides compounds of general formula (I) wherein A, X, m, R, N, R, Z, Z, Q, R, R, R, R, R, R, t and Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy 

Benzimidazol derivatives modulate chemokine receptors

The invention provides compounds of general formula (I), wherein R, X, Y, n, R, Z, Z, A, A, Q, R, R, R, R, R, R, t and Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy 

Amides, preparation and therapeutic use as modulators of CCR-receptor activity

The invention provides compounds of general formula (I) wherein m, n, Z, Z, R, R, R, R, R, R, Rand Rare as defined in the specification, process for their preparation, pharmaceutical compositions containing them and their use in therapy.

The invention provides compounds of general formula (I) wherein Q, R, R, R, R, R, R, R, and Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Hydroxyalkyl compounds

 The invention provides compounds of general formula (I) wherein m, n, Q, Z, Z, R, R, R, R, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Peptides being absorbable by the epithelial cell lining in a mammal resulting in a modulated immune response and thereby a therapeutic effect against disease, formulations containing such peptides and uses thereof.

Peptides with immunomodulatory effects

Novel homodimers that include cysteine-containing peptides having 4-15 amino acid residues can be administered to modulate the immune response in an animal.

Growing community of inventors

Lund, Sweden

Tomas Eriksson